Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties

Journal of Medicinal Chemistry

Volumn 42, Issue 20, 1999, Pages 4239-4249

  Hu, Lain Yen ^a   Ryder, Todd R ^a   Rafferty, Michael F ^a   Feng, M Rose ^a   Lotarski, Susan M ^a   Rock, David M ^a   Sinz, Michael ^a   Stoehr, Sally J ^a   Taylor, Charles P ^a   Weber, Mark L ^a   Bowersox, S Scott ^b   Miljanich, George P ^b   Millerman, Elizabeth ^b   Wang, Yong Xiang ^b   Szoke, Balazs G ^b  

^a PFIZER INC   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ALKYLATION; AMINATION; ARTICLE; CALCIUM TRANSPORT; CHEMICAL MODIFICATION; DRUG SYNTHESIS; NERVE EXCITABILITY; NERVE FUNCTION; NEUROTRANSMITTER RELEASE; RECEPTOR BLOCKING; STROKE; SYNAPTIC TRANSMISSION;

ACOUSTIC STIMULATION; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTICONVULSANTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELL LINE; HEART RATE; HUMANS; ION CHANNEL GATING; MALE; MICE; MICE, INBRED DBA; MICROSOMES, LIVER; NEURONS; PAIN MEASUREMENT; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SEIZURES;

EID: 0033533868     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902739     Document Type: Article

References (48)

1. (a) Bowersox, S. S.; Valentino, K. L.; Luther, R. R. Neuronal voltage-sensitive calcium channels. Drug News Perspect. 1994, 7, 261-268.
2. (b) Scraibine, A. Calcium channel antagonists as neuroprotective agents. Neuroprot. CNS Dis. Baer, P. R., Beal, M. F., Eds.; Dekker: New York, 1997; pp 27-51.
3. (c) Gilmore, J.; Dell, C.; Bowman D.; Lodge, D. Neuronal calcium channels. Annu. Report Med. Chem. 1995, 30, 51-60.
4. 2+ channels in mammalian central neurons. Trends Neurosci. 1995, 18, 89-98.
5. (e) Miljanich, G. P.; Ramachandran, J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implica1 tions. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 704-734.
6. (f) Barone, F. C.; Feuerstein, G. Z.; Spera, R. P. A. Calcium channel blockers in cerebral ischemia. Expert Opin. Invest. Drugs 1997, 6, 501-519.
7. (a) Bowersox, S. S.; Singh, T.; Luther, R. R.Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats. Brain Res. 1997, 747, 343-347.
8. (b) Bowersox, S. S.; Gadbois, T.; Singh, T.; Pettus, M.; Wang, Y.; Luther, R. R. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Ther. 1996, 279, 1243-1249.
9. (c) Verweij, B. H.; Muizelaar, J. P.; Vinas, F. C.; Peterson, P. L.; Xiong, Y.; Lee, C. P. Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111). Neurol. Res. 1997, 19, 334-339.
10. (d) Malmberg, A. B.; Yaksh, T. L. Effect of continuous intrathecal infusion of ω-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995, 60, 83-90.
11. (e) Chaplan, S. R.; Pogrel, J. W.; Yaksh, T. L. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J. Pharmacol. Exp. Ther. 1994, 269, 1117-23.
12. (f) Valentino, K.; Newcomb, R.; Gadbois, T.; Singh, T.; Bowersox, S.; Bitner, S.; Justice, A.; Yamashiro, D.; Hoffman, B. B.; et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7894-7897.
13. (g) Mathur, V. S.; McGuire, D.; Bowersox, S. S.; Miljanich, G. P.; Luther, R. R. Neuronal N-type calcium channels: new prospect in pain therapy. Pharm. News 1998, 5, 25-29.
14. (h) Bowersox, S. S.; Luther, R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998, 36, 1651-1658.
15. (i) Bowersox, S.; Tich, N.; Mayo, M.; Luther, R., SNX-111. Antinociceptive agent. N-type voltage-sensitive calcium channel blocker. Drugs Future 1998, 23, 152-160.
16. (a) Olivera, B. M.; Milijanich, G. P.; Ramachandran, J.; Adams, M. E. Calcium channel diversity and neurotransmitter release: The ω-conotoxins and ω-agatoxins. Annu. Rev. Biochem. 1994, 63, 823-867.
17. (b) Pringle, A. K.; Benham, C. D.; Sim, L.; Kennedy, J.; Iannotti, F.; Sundstrom, L. E. Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampalslice cultures. Stroke (Dallas) 1996, 27, 2124-2130.
18. (c) Nadasdi, L.; Yamashiro, D.; Chung, D.; Tarczy-Hornoch, K.; Adriaenssens, P.; Ramachandran, J. Structure-Activity Analysis of a Conus Peptide Blocker of N-Type Neuronal Calcium Channels. Biochemistry 1995, 34, 8076-81,
19. Cox, B.; Denyer, J. C. N-Type calcium channel blockers in pain and stroke. Expert. Opin. Ther. Pat 1998, 8, 1237-1250.
20. (a) Cohan, S. L.; Redmond, D. J.; Chen, M.; Wilson, D.; Cyr, P. Flunarizine blocks elevation of free cytosolic calcium in synaptosomes following sustained depolarization. J. Cereb. Blood Flow Metab. 1993, 13, 947-954.
21. (b) Cohan, S. L.; Chen, M.; Redmond, D.; Wilson, D. Depolarization-induced presynaptic calcium accumulation may occur by an N-type channel that is blocked by flunarizine. Ann. N. Y. Acad. Sci. 1991, 635, 397-399.
22. (a) Grantham, C. J.; Main, M. J.; Cannell, M. B. Fluspirilene block of N-type calcium current in NGF-differentiated PC12 cells. Br. J. Pharmacol. 1994, 111, 483-488.
23. (b) Sah, D. W.; Bean, B. P. Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. Mol. Pharmacol. 1994, 45, 84-92.
24. Yuen, P.; Schelkun, R. M.; Szoke, B.; Tarczy-Hornoch, K. Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 1998, 8, 2415-2418.
25. (a) Benham, C. D.; Brown, T. H.; Cooper, D. G.; Evans, M. L.; Harries, M. H.; Herdon, H. J.; Meakin, J. E.; Murkitt, K. L.; Patel, S. R.; et al. SB 201823-A, a neuronal calcium antagonist is neuroprotective in two models of cerebral ischemia. Neuropharmacology 1993, 32, 1249-1257.
26. (b) Barone, F. C.; Lysko, P. G.; Price, W. J.; Feuerstein, G.; Al-Baracanji, K. A.; Benham, C. D.; Harrison, D. C.; Harries, M. H.; Bailey, S. J.; Hunter, A. J. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke (Dallas) 1995, 26, 1683-1689.
27. (a) Wood, N. I.; Barone, F. C.; Benham, C. D.; Brown, T. H.; Campbell, C. A.; Cooper, D. G.; Evans, M. L.; Feuerstein, G. Z.; Hamilton, T. C. The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J. Cereb. Blood Flow Metab. 1997, 17, 421-429.
28. (a) Jakobsen, P.; Kanstrup, A.; Lundbeck, J. M. Piperidine compounds, their preparation and use. WO 9201672, 1992.
29. (b) Barone, F. C.; Price, W. J.; Jakobsen, P.; Sheardown, M. J.; Feuerstein, G. Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol., Biochem. Behav. 1994, 48, 77-85.
30. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br. J. Pharmacol 1997, 722, 37-42.
31. 2+ channel in rat dorsal root ganglion neurons, J. Pharmacol. Exp. Ther. 1997, 280, 1184-1191.
32. Warming, T.; Christophersen, P.; Moeller, A.; Peters, D.; Axelsson, O.; Nielsen, E. O. Synthesis and biological activity of the neuronal calcium channel blocker 2-amino-1-(2,5-dimethoxyphenyl-5-trifluoromethyl benzimidazole (NS-649). Bioorg. Med. Chem. Lett. 1996, 6, 245-248.
33. (a) Bleakman D.; Boot, J. R.; Dell, C. Gilmore, J.; Harvey, J.; Hotten, T. M.; O'Brien, A. J.; Palombo, L.; Suarez, A. S.; Tupper, D. E. Novel antagonists of neuronal (non-L-type) voltage-dependent calcium channels. 15th European Federation of Medicinal Chemistry International Symposium on Medicinal Chemistry, Edinburgh, Scotland, 1998; p 133.
34. + channel inhibitors in vitro and in global cerebral ischemia in vivo. Eur. J. Pharmacol. 1997, 332, 121-131.
35. Malone, T.; Booth, J.; Campbell, G.; Cody, W.; Geer, J.; He, J.; Hu, L.; Lescosky, L. J.; Miljanich, G.; Nadasdi, L.; Rafferty, M. F.; Rock, D.; Sercel, A.; Stoehr, S.; Song, S.; Szoke, B. G.; Tarczy-Hornoch, K.; Taylor, C. P.; Urge, L.; Vartanian, M.; Weber, M.; Yi, S. Identification and SAR Studies of PD 151307, A Novel N-type Calcium Channel Blocker. Abstracts of Papers, 217th National Meeting of the American Chemical Society, Anaheim, CA, March, 1999; American Chemical Society: Washington, DC, 1999; MEDI 122.
36. Hu, L.; Ryder, T. R.; Rafferty, M. F.; Cody, W. L.; Lotarski, S. M.; Miljanich, G. P.; Millerman, E.; Rock, D. M.; Song, Y.; Stoehr, S. J.; Szoke, B. G.; Taylor, C. P.; Vartanian, M. G.; Weber, M. L.; N,N-Dialkyl-dipeptidyl-amines as Novel N-Type Calcium Channel Blockers. Bioorg. Med. Chem. Lett. 1999, 9, 907-912.
37. De Sarro, G. B.; Meldrum, B. S.; Nistico, G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. G. Br. J. Pharmacol. 1988, 93, 247-256.
38. 2+ channel toxins in DBA/2 mice. Phychopharmacology 1996, 126, 85-90.
39. Examples of CNS agents containing 4-aminopiperidine motifs: Fentanyl citrate, Trefentamil hydrochloride, Ocfentamil hydrochloride, and Lofentanil oxalate for analgesic; Pipamperone for antipsychotic. USAN and the USP dictionary of drug names; Fleeger, C. A., Ed.; United States Pharmacopeial Convention, Inc.: Rockville, MD, 1994; pp 383, 473, 681, 522, 277.
40. + channel blockers are active in the DBA/2 model: (a) Chapman, A. G.; Croucher, M. J.; Meldrum, B. S. Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures. Arzneim.-Forsch. 1984, 34 (10), 1261-1264.
41. (b) Seyfried, Thomas N. Audiogenic seizures in mice. Fed. Proc., Fed. Am. Soc. Exp. Biol. 1979, 38, 2399-2404.
42. (c) Ryder, T. R.; Hu, L.-Y.; Rafferty, M. F.; Lotarski, S. M.; Rock, D. M.; Stoehr, S. J.; Taylor, C. P.; Weber, M. L.; Miljanich, G. P.; Mollerman, E.; Szoke, B. G. Structure-activity relationship at the central phenyl group in a series of nonpeptidyl N-type calcium channel anatagonists. Bioorg. Med. Chem. Lett. 1999, 9, 2453-2468.
43. (a) Clarke, F. H.; Gahoon, N. M.Partition Coefficients by Curve Fitting: The Use of Two Different Octanol Volumes in a Dual-Phase Potentiometric Titration. J. Pharm. Sci. 1996, 85, 178-83.
44. (b) Clarke, F. H.; Cahoon, N. M. Potentiometric Determination of the Partition and Distribution Coefficients of Dianionic Compounds. J. Pharm. Sci. 1995, 84, 53-4.
45. (c) Clarke, F. H.; Cahoon, N. M. Ionization constants by curve fitting: determination of partition and distribution coefficients of acids and bases and their ions. J. Pharm. Sci. 1987, 76, 611-20.
46. 2+ channel currents in cultured rat superior cervical ganglion neurons. Drug Dev. Res. 1997, 41, 85-90.
47. (a) Parker, R. B. Inhibition of spontaneous and methamphetamine-induced locomotor activity with centrally active drugs in mice. Life Sci. 1978, 22, 1067-76.
48. (b) Koster, R.; Anderson, M.; DeBeer, E. Acetic acid for analgesic screening. Fed. Proc. 1959, 22, 412.